BioEclosion

Thank you for visiting us at 4YFN 2025 @MWC

Posted on 07/03/202507/03/2025 by Arnau Pallares

What a week at 4 Years From Now (4YFN) 2025 Congress held within the Mobile World Congress (MWC) in Barcelona

BioEclosion proudly presented its prototype of next-generation biosensor-based diagnostic device at the UAB stand (8.1C42) to 4YFN-MWC attendees. After 4 busy days presenting our patented technology, we are even more commited and motivated to fulfill our mission: enhance early disease detection and healthcare accessibility through innovative and reliable technology.

The opportunity to present at 4YFN 2025 has allowed BioEclosion to reach many interesting contacts for our development.

Thank you all for visiting us, and hopefully see you again very soon!

#BioEclosion #4YFN #MWC25 #Diagnostics #Biosensors #Innovation #UAB #Startups #HealthcareTechnology #PointOfCare

BioEclosion at 4YFN 2025 Mobile World Congress. Advancing Innovation in Diagnostics

Posted on 27/02/202527/02/2025 by Isabel Pividori

We are thrilled to announce that BioEclosion will be participating in 4 Years From Now (4YFN), the premier event for startups, held under the umbrella of the Mobile World Congress (MWC) Barcelona from March 3-6, 2025. As a spin-off of the Universitat Autònoma de Barcelona (UAB), BioEclosion is proud to be among the pioneering companies featured at the UAB stand (8.1C42).

At BioEclosion, we specialize in developing next-generation biosensor-based diagnostic devices, providing rapid, accurate, and cost-effective solutions for point-of-care testing. Our mission is to enhance early disease detection and healthcare accessibility through innovative and reliable technology.

The 4YFN event serves as a dynamic platform for emerging businesses, researchers, and innovators to showcase cutting-edge solutions in mobile and digital technologies. UAB’s presence will highlight the impact of 31 spin-offs, startups, and entrepreneurial projects, reinforcing its commitment to innovation and research-driven business growth.

We invite you to connect with us at 4YFN 2025 to explore how our biosensor technology is shaping the future of diagnostics!

📍 Find us at UAB Stand 8.1C42
📅 March 3-6, 2025
📢 Let’s revolutionize healthcare together!

#BioEclosion #4YFN #MWC25 #Diagnostics #Biosensors #Innovation #UAB #Startups #HealthcareTechnology #PointOfCare

Bioeclosion joins ‘Industrial Startups Day’ by S2 Xpeed and ‘Forùm Arquímedes’ by PRUAB

Posted on 16/12/202418/12/2024 by Arnau Pallares

At Bioeclosion, the last month of 2024 has been truly inspiring!

As a spin-off from UAB, Bioeclosion participated in the annual ‘Fòrum Arquímedes’ event, which brought together all spin-off companies from the university at the ‘Casa de la Convalescència’ in Barcelona, Spain, on December 10th. It was a networking event aimed at building community and inspiring entrepreneurs from UAB.

Besides, the end of the S2 Xpeed acceleration program provided us with the opportunity to present our company and prototypes at the Industrial Startups Day. It was held as part of Tech Spirit Barcelona 2024, one of the region’s major events for startups and innovative companies. The event took place at Llotja de Mar in Barcelona, Spain, on December 13th, offering a platform to share our vision on the future of Rapid Diagnostic Tests and to network with collaborators and investors. Our fellow S2 Xpeed program cohort members—AiSense, Curatio, ELNAV.ai, and Ubyko—were also present.

Featuring BioEclosion cartridge in biosensing research in breast cancer detection based on exosomes

Posted on 28/03/202405/04/2024 by Arnau Pallares

🌟 Transforming Breast Cancer Diagnosis. BioEclosion’s breakthrough in biosensing technology 🌟

In an exciting development for the field of medical diagnostics, our latest product, the specialized cartridge for biosensing applications, has been featured in a pioneering study published in Biosensors and Bioelectronics. This study, titled “Peptide-based biosensing approaches for targeting breast cancer-derived exosomes”, marks a significant milestone in the non-invasive detection of breast cancer through advanced biosensor technology.

Why This Research Matters
Breast cancer, a leading cause of cancer-related deaths worldwide, requires innovative diagnostic methods for early detection and treatment. The research conducted utilized our cutting-edge cartridge in developing an electrochemical biosensor that precisely targets and quantifies exosomes derived from breast cancer cells. Exosomes, nanovesicles present in all biological fluids, are key biomarkers for cancer due to their molecular composition, reflecting the pathological state of their cells of origin.

Key innovations

Use of phage display technology to select peptides with high specificity for exosomes derived from breast cancer cells, demonstrating the effectiveness of peptide-based biosensors as cost-effective and stable alternatives to traditional antibodies.
Development of a magneto-actuated immunoassay and electrochemical biosensor integrated with our cartridge technology for the detection and quantification of breast cancer-derived exosomes in serum, showcasing a significant improvement in sensitivity and specificity.
Achievement of a lower limit of detection for breast cancer-derived exosomes, highlighting the potential for early diagnosis and monitoring of breast cancer in a non-invasive manner.

Our commitment to innovation
At BioEclosion, we are proud to contribute to such transformative research that has the potential to revolutionize the diagnosis and treatment of breast cancer. Our dedication to providing innovative solutions ensures healthcare professionals can offer more accurate, early detection methods, improving patient outcomes and quality of life.

Looking ahead
The successful application of our cartridge in this study is just the beginning. We are excited to continue our work with researchers and clinicians worldwide, pushing the boundaries of diagnostic technology and making a tangible impact on patient care.

For more details on the study and our biosensing technology, visit Biosensors and Bioelectronics.

#BioEclosion #BreastCancerAwareness #InnovativeDiagnostics #BiosensingTechnology #EarlyDetectionSavesLives

https://doi.org/10.1016/j.bios.2024.116211

.

New article in Sensors and Actuators B

Posted on 23/12/202317/05/2024 by Arnau Pallares

Mycobacterium detection method combining filtration, immunomagnetic separation, and electrochemical readout in a portable biosensing device. Melania Mesas Gómez, Bárbara Molina-Moya, Bárbara Camila de Araújo, Arnau Pallarès-Rusiñol, Jofre Ferrer-Dalmau, Maria Valnice Boldrín Zanoni, José Domínguez, Esther Julian, María Isabel Pividori Gurgo. Sensors and Actuators B: Chemical. Available online 23 December 2023, 135211. In Press, Journal Pre-proof. https://doi.org/10.1016/j.snb.2023.135211

Highlights

Innovative preconcentration strategy combines magnetic particles and filtration
One-Step Immunomagnetic Separation and Labeling reduces analysis time
The user-friendly cartridge design reduces the need for manual intervention
The handheld device for the electrochemical readout offers portability and on-site testing capabilities
LOD significantly improved by 10³-fold to 5 CFU mL^-1, reaching regulatory limits.

Bioeclosion participates in S2 Xpeed acceleration program and ‘Fira de la Innovació’ at UAB

Posted on 29/10/202416/12/2024 by Arnau Pallares

Bioeclosion has been selected to participated in Cohort #3 of S2 Xpeed acceleration program, starting on September 2024. This 4-months program is focused on helping European hardware-based startups to advance from a functional prototype to first industrial series, complemented with market validation, and a growth strategy. Together with Bioeclosion, 4 more startups are joining this exciting program: Ubyko (ES), Curatio (NL), Elnav.ai (HR), and AI.Sense (SK).

Besides, Dr. Ferrer-Dalmau, CEO of Bioeclosion, and Dr. Pallarès, have recently participated in the 2024 Edition of ‘Fira de la Innovació‘ of UAB, a matchmaking event of all research groups from UAB Campus (UAB, CSIC, IRTA) together with spinoff companies and industrial stakeholders located at UAB Campus. It was a great meeting point to find new potential collaborators to join with Bioeclosion and advance in the development of the company.

Join us at the Health Revolution Congress on May 16th in Barcelona for an inspiring session on the New Era on Medical Devices

Posted on 16/05/202416/12/2024 by Arnau Pallares

🚀 Discover cutting-edge advancements in agile codesign, prototyping, and industrialization organized by EURECAT

We are delight to announce the participation of Bioeclosion and María Isabel Pividori, CTO at Bioeclosion, who will share their expertise and insights on the future of medical device innovation. Don’t miss out on this opportunity to learn from leaders in the field!

📅 Date: May 16th
🕐 Time: 11:30 AM – 1:30 PM
📍 Venue: Recinte Modernista de Sant Pau, Barcelona

Agenda Highlights:

11:30 AM – 11:35 AM: Introduction by Eva Rosell, CEO at Barcelona Health Hub, and Felip Miralles, Executive Director of Health Technologies at Eurecat.
11:35 AM – 11:55 AM: Life Cycle for the Agile Development of Medical Devices by Irene Rafols and David Marí from Eurecat.
11:55 AM – 12:05 PM: Regulation Roadmap in Medical Devices by Francisco Rodriguez from Asphalion.

12:05 PM – 1:25 PM: Panel Discussion: “New Era on Medical Devices: Agile Codesign, Prototyping, and Industrialization” moderated by Felip Miralles from Eurecat. This insightful discussion will cover:

Challenges for Emerging Medical Device Startups: Explore the key challenges that startups face in today’s rapidly evolving technological landscape.
The Role of Agile Codesign and Prototyping: Understand how agile methodologies can accelerate the innovation process and improve the efficiency of medical device development.
Collaborative Approaches: Learn how partnerships between startups, regulatory bodies, and established industry players can foster the development and adoption of next-generation medical devices.
Integrating Agile Methodologies with Regulatory Requirements: Discover strategies to align agile practices with regulatory frameworks to ensure compliance while maintaining flexibility.
Utilizing Agile Planning Tools: Find out how to use agile tools for effective regulatory-level record-keeping, stakeholder management, and technical requirement documentation. Panelists:

Xavier Castells, CEO at DIPNEO
Mireia Claramunt, CTO at EPHION EHEALTH
Juan Roldan, CEO at GIROMED
Maira Isabel Pividori Gurgo, CTO at Bioeclosion
Ronen Zioni, CEO at Excelenciatech
1:20 PM – 1:30 PM: Final Conclusions and Key Takeaways

For more information, visit Health Revolution Congress.

#HealthRevolutionCongress #MedicalDevices #Innovation #Bioeclosion #Pividori #AgileDevelopment #HealthcareInnovation #BarcelonaHealthHub

Discover Bioeclosion Live at the 4YFN MWC Congress in Barcelona

Posted on 29/02/202416/12/2024 by Arnau Pallares

Bioeclosion SL is currently participating in the 4YFN (4 Years From Now) Congress in Barcelona, having been invited by UAB as a spin-off company of the university. 4YFN serves as a parallel event for startups during the Mobile World Congress, the largest event in the mobile industry.

Dr. Jofre Ferrer-Dalmau, CEO of Bioeclosion, along with Dr. Arnau Pallarès, are actively participating in the event and are presenting the Bioeclosion prototype to potential investors and collaborators. This opportunity proves invaluable for showcasing our technology at a specialized event tailored for startups.

BioEclosion Presents Breakthrough Technology and Investment Opportunity at UAB Forum, closure of Arquímedes acceleration program

Posted on 16/12/202316/12/2024 by Arnau Pallares

Last week, Dr. Jofre Ferrer-Dalmau, CEO, presented Bioeclosion at the UAB Investment forum, as closure event of Arquímedes acceleration program. Dr. Ferrer-Dalmau explained Bioeclosion technology, goals and potentiality at a dozen of investors and VC managers. It was highlithed the recently opened Pre-Series A round to complete the development of Bioeclosion MVP.

As a UAB spin-off company, Bioeclosion was invited to join Arquímedes program aiming to help accelerate the company to fulfill its mission and goals. The program combined specialist workshops, personalized mentoring sessions, and an investment forum.

The event was located at Casa de Convalescència, Hospital de Sant Pau, Barcelona, on 13th December 2023.

Bioeclosion SL participates in BioSpain 2023 and Fira de la Innovació de la UAB

Posted on 19/10/202316/12/2024 by Arnau Pallares

Dr. Jofre Ferrer-Dalmau, CEO of BioEclosion, has recently participated in the last edition of BioSpain Congress, organized in Barcelona, 26-28th of September 2023. BioSpain 2023 was a great opportunity to meet with leading companies of biotech sector in Spain, looking forward to find new partners and develop new collaborations.

And last week, Dr. Arnau Pallarès, research scientist in BioEclosion, has participated in the 1st edition of Fira de la Innovació from Universitat Autònoma de Barcelona, in Bellaterra, 17th October 2023. This event has brought together research groups and spinoffs companies that emerged from the UAB. It was a great opportunity to meet new collaborators and companies around the UAB.
Beasides, Bioeclosion has also attended the inaugural session of the Arquímedes startup acceleration program, organized by the UAB Research Park.